WARNEX
MEDICAL LABORATORIES

deCODE
Genetic Risk Assessment Tests

deCODE ProstateCancer™
Assesses the risk of prostate cancer. The test detects 27 genetic variants associated with risk of prostate cancer in males of European descent, which have been shown to have significant impacts on a man's assessed lifetime risk. For African-Americans and East Asians, the test detects 9 and 12 genetic variants, respectively, that are associated with risk of prostate cancer.

deCODE MI™
Assesses the risk of myocardial infarction (heart attack). The test detects 8 SNPs in the sequence of the genome associated with risk of heart attack. These include the chromosome 9p21 variants discovered by deCODE, the highest impact and best validated genetic risk factors for heart attack yet found. The test provides a novel means of detecting the substantial genetic component to overall susceptibility to heart attack, risk that appears to be independent of well known risk factors such as elevated cholesterol and hypertension.

deCODE AF™
Assesses the risk of atrial fibrillation (AF). In-patient post-stroke cardiac monitoring misses a large proportion of intermittent AF. This test enables physicians to target and personalize the use of ambulatory cardiac monitoring and optimize stroke prevention in those found to have AF.

deCODE Clopidogrel™
Identifies patients who may need adjustment of their Clopidogrel dose or who should be put on an alternative medication to prevent recurrent adverse cardiovascular events. The test analyzes 5 SNPs in the CYP2C19 gene that affect response to the anti-platelet drug Clopidogrel.

deCODE BreastCancer™
Detects 16 genetic risk factors for the common forms of breast cancer. The common forms of the disease account for approximately 95% of all breast cancers. These markers have been discovered and validated in case-control studies in multiple populations, involving tens of thousands of breast cancer patients and hundreds of thousands of controls.

deCODE T2™
Assesses the risk of type 2 diabetes, independent of family history and obesity. The test detects DNA markers that have been widely replicated as risk factors for type 2 diabetes. The deCODE TCF7L2 marker is the strongest genetic risk factor discovered so far for type 2 diabetes and has been validated in over 40 populations and multiple continental ancestries.

deCODE Glaucoma™
Assesses the risk of exfoliation glaucoma. The test detects two SNP markers associated with increased risk of exfoliation glaucoma. They are located in a gene called LOXL1, and about 10-30% of all primary open angle glaucoma patients have the at-risk versions of these SNPs in the LOXL1 gene.

deCODE Cancer
DNA-based test panel that measures risk for 7 common cancers: colon, lung, bladder, thyroid and basal cell carcinoma, as well as breast and ovarian cancer in women and prostate and testicular cancer in men.

deCODE Cardiovascular
Assesses the risk of 6 cardiovascular diseases including myocardial infarction, type 2 diabetes, atrial fibrillation, abdominal aortic aneurysm, intracranial aneurysm and venous thromboembolism, as well as clopidogrel responsiveness.

deCODE Complete
Analyzes risk factors for more than 45 common diseases and medical conditions, including all of the aforementioned individual tests. This scan focuses on medical conditions that can either be prevented through altered lifestyle or have better treatment outcomes if detected early. It is the most comprehensive genetic scan available for evaluating risk of common diseases.

About Warnex Medical Laboratories
Warnex Medical Laboratories provides specialized clinical services for the healthcare and pharmaceutical industries using the most advanced technologies in a highly rigorous quality system environment. Warnex Medical Laboratories is accredited by the Standards Council of Canada under ISO 15189.

SCC Accredited LAB
LAB Accrédité CCN

Oct. 3, 2011

3885 Industriel Blvd., Laval, Quebec, Canada H7L 4S3 T (450) 663-6724 F (450) 663-4428 www.warnex.ca

WARNEX MEDICAL LABORATORIES

deCODE
Genetic Risk Assessment Tests

Test (Disease/Trait)	Available as Individual Test	Part of			Ancestry Applicability		
		Cardio	Cancer	Complete	European	East Asian	African American
Myocardial infarction	x	x		x	x	x	
Type 2 diabetes	x	x		x	x	x	x
Atrial fibrillation	x	x		x	x	x	
Clopidogrel	x	x		x	x	x	x
Intercranial aneurysm		x		x	x	x	
Abdominal aortic aneurysm		x		x	x		
Venous thromboembolism		x		x	x		
Prostate cancer	x		x	x	x	x	x
Testicular cancer			x	x	x		
Breast cancer	x		x	x	x	x	
Ovarian cancer			x	x	x		
Colon cancer			x	x	x	x	
Lung cancer			x	x	x		
Thyroid cancer			x	x	x		
Bladder cancer			x	x	x		
Basal cell carcinoma			x	x	x		
Exfoliation glaucoma	x			x	x		
Alcohol flush reaction				x	x	x	
Bitter taste perception				x	x	x	x
Lactose intolerance				x	x	x	x
Psoriasis				x	x	x	
Rheumatoid arthritis				x	x	x	
Age-related macular degeneration (AMD)				x	x	x	
Asthma				x	x	x	
Alzheimer's disease				x	x	x	

The following diseases and medical conditions are also included in the Complete scan but are only applicable to individuals of European ancestry:

- ABO blood group
- Celiac disease
- Chronic kidney disease
- Chronic lymphocytic leukemia
- Chronic obstructive pulmonary disease
- Crohn's disease
- Essential tremor
- Eye colour
- Gallstones
- Gout
- Hematochromatosis
- Hypertension
- Kidney stones
- Male pattern baldness
- Nicotine dependence
- Obesity
- Pancreatic cancer
- Restless legs syndrome
- Statin induced myopathy
- Systemic lupus erythematosus
- Type 1 diabetes
- Ulcerative colitis
- Warfarin metabolism

3885 Industriel Blvd., Laval, Quebec, Canada H7L 4S3 T (450) 663-6724 F (450) 663-4428 www.warnex.ca